Literature DB >> 29192759

Sulfur Nanoparticles with Novel Morphologies Coupled with Brain-Targeting Peptides RVG as a New Type of Inhibitor Against Metal-Induced Aβ Aggregation.

Jing Sun1, Wenjie Xie1, Xufeng Zhu1, Mengmeng Xu1, Jie Liu1.   

Abstract

Functionalized nanomaterials, which have been applied widely to inhibit amyloid-β protein (Aβ) aggregation, show enormous potential in the field of prevention and treatment of Alzheimer's disease (AD). A significant body of data has demonstrated that the morphology and size of nanomaterials have remarkable effects on their biological behaviors. In this work, we proposed and designed three kinds of brain-targeting sulfur nanoparticles (RVG@Met@SNPs) with novel morphologies (volute-like, tadpole-like, and sphere-like) and investigated the effect of different RVG@Met@SNPs on Aβ-Cu2+ complex aggregation and their corresponding neurotoxicity. Among them, the sphere-like nanoparticles (RVG@Met@SS) exhibited the most effective inhibitory activity, due to their unique mini size effect, and they reduced 61.6% the Aβ-Cu2+ complex aggregation and increased 92.4% SH-SY5Y cell viability in a dose of 10 μg/mL. In vitro and in vivo, the abilities of different morphologies of RVG@Met@SNPs to cross the blood-brain barrier (BBB) and target brain parenchymal cells were significantly different. Moreover, improvements in learning disability and cognitive loss were shown in the transgenic AD mice model using the Morris water maze test after multiple doses of RVG@Met@SNPs treatment. In general, the purpose of this research is to develop a biological application of sulfur nanoparticles and to provide a novel functionalized nanomaterial to treat AD.

Entities:  

Keywords:  Alzheimer’s disease; amyloid-β protein; blood−brain barrier; sulfur nanoparticles

Mesh:

Substances:

Year:  2017        PMID: 29192759     DOI: 10.1021/acschemneuro.7b00312

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  3 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 2.  Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases.

Authors:  Sureshbabu Ram Kumar Pandian; Kevin Kumar Vijayakumar; Sankaranarayanan Murugesan; Selvaraj Kunjiappan
Journal:  Heliyon       Date:  2022-06-04

Review 3.  Nanotechnology Therapy for Alzheimer's Disease Memory Impairment Attenuation.

Authors:  Samo Ribarič
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.